Research work · 2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep M. Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Lordick Obermannova, Gyorgy Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David Craig Portnoy, Eric Van Cutsem, Axel F. Grothey, Jana Prausová, Pilar García Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah
The Lancet Oncology